BeOne Medicines (NASDAQ:ONC) CEO John Oyler Sells 3,693 Shares of Stock

BeOne Medicines Ltd. – Sponsored ADR (NASDAQ:ONC) CEO John Oyler sold 3,693 shares of the business’s stock in a transaction that occurred on Tuesday, June 16th. The stock was sold at an average price of $265.55, for a total transaction of $980,676.15. Following the sale, the chief executive officer owned 2,043 shares of the company’s stock, valued at approximately $542,518.65. This represents a 64.38% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

John Oyler also recently made the following trade(s):

• On Thursday, June 11th, John Oyler sold 1,949 shares of BeOne Medicines stock. The stock was sold at an average price of $257.24, for a total transaction of $501,360.76.
• On Monday, June 8th, John Oyler sold 4,940 shares of BeOne Medicines stock. The shares were sold at an average price of $270.56, for a total transaction of $1,336,566.40.

BeOne Medicines Stock Up 2.8%

Shares of NASDAQ:ONC traded up $7.47 during midday trading on Thursday, hitting $270.15. 367,884 shares of the company’s stock traded hands, compared to its average volume of 260,552. The company has a debt-to-equity ratio of 0.20, a quick ratio of 3.27 and a current ratio of 3.64. The company has a market cap of $29.64 billion, a PE ratio of 60.44 and a beta of 0.49. The firm’s fifty day moving average price is $296.83 and its two-hundred day moving average price is $312.94. BeOne Medicines Ltd. – Sponsored ADR has a twelve month low of $239.25 and a twelve month high of $385.22.

BeOne Medicines (NASDAQ:ONC) last announced its quarterly earnings results on Wednesday, April 1st. The company reported $0.25 earnings per share (EPS) for the quarter. BeOne Medicines had a return on equity of 12.06% and a net margin of 8.94%.The firm had revenue of $1.51 billion during the quarter. On average, equities research analysts anticipate that BeOne Medicines Ltd. – Sponsored ADR will post 6.14 EPS for the current fiscal year.

Wall Street Analyst Weigh In

ONC has been the subject of a number of recent research reports. Royal Bank Of Canada increased their target price on BeOne Medicines from $425.00 to $436.00 and gave the company an “outperform” rating in a research note on Tuesday, June 2nd. Guggenheim boosted their price target on BeOne Medicines from $410.00 to $420.00 and gave the stock a “buy” rating in a research report on Thursday, May 7th. Barclays upped their price target on BeOne Medicines from $405.00 to $409.00 and gave the stock an “overweight” rating in a report on Thursday, May 7th. Jefferies Financial Group downgraded shares of BeOne Medicines from a “buy” rating to a “hold” rating and lowered their price objective for the company from $420.00 to $290.00 in a research report on Monday, March 16th. Finally, Zacks Research upgraded shares of BeOne Medicines from a “hold” rating to a “strong-buy” rating in a research note on Thursday, June 4th. Two investment analysts have rated the stock with a Strong Buy rating, eleven have given a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, BeOne Medicines presently has an average rating of “Moderate Buy” and a consensus price target of $390.00.

Institutional Trading of BeOne Medicines

Hedge funds and other institutional investors have recently modified their holdings of the business. Bank of America Corp DE purchased a new position in BeOne Medicines in the second quarter valued at about $67,657,000. Man Group plc purchased a new stake in BeOne Medicines during the 2nd quarter worth approximately $59,031,000. Capital International Investors raised its position in shares of BeOne Medicines by 3.3% in the 3rd quarter. Capital International Investors now owns 5,046,058 shares of the company’s stock valued at $1,716,883,000 after purchasing an additional 161,052 shares in the last quarter. BNP Paribas Financial Markets acquired a new position in shares of BeOne Medicines in the 2nd quarter valued at approximately $38,337,000. Finally, First Trust Advisors LP boosted its stake in shares of BeOne Medicines by 91.9% during the 1st quarter. First Trust Advisors LP now owns 241,426 shares of the company’s stock valued at $71,696,000 after buying an additional 115,601 shares during the last quarter. 48.55% of the stock is owned by hedge funds and other institutional investors.

BeOne Medicines Company Profile

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.